King Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for KING PHARMS, and when can generic versions of KING PHARMS drugs launch?
KING PHARMS has twenty-seven approved drugs.
There is one US patent protecting KING PHARMS drugs.
There are two patent family members on KING PHARMS drugs in two countries and nine supplementary protection certificates in six countries.
Drugs and US Patents for King Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
King Pharms | PROCANBID | procainamide hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020545-002 | Jan 31, 1996 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
King Pharms | SKELAXIN | metaxalone | TABLET;ORAL | 013217-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-001 | May 25, 2001 | AB1,AB3 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for King Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
King Pharms Llc | ALTACE | ramipril | CAPSULE;ORAL | 019901-002 | Jan 28, 1991 | 5,061,722 | ⤷ Try a Trial |
King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-005 | May 25, 2001 | 7,067,148 | ⤷ Try a Trial |
King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-007 | May 25, 2001 | 7,101,569 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for KING PHARMS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2004-11-04 |
➤ Subscribe | Extended-release Capsules | 45 mg and 75 mg | ➤ Subscribe | 2009-07-30 |
➤ Subscribe | Extended-release Capsules | 30 mg, 60 mg, 90 mg and 120 mg | ➤ Subscribe | 2007-06-04 |
International Patents for King Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2626027 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2007094825 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for King Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1539166 | SPC/GB13/070 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. Q; REGISTERED: UK EU/1/13/833 20130626 |
0350733 | SPC/GB03/034 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313 |
1539166 | 2013C/064 | Belgium | ⤷ Try a Trial | PRODUCT NAME: DEXTROMETHORPHANE OU UN SEL, PRCURSEUR DE DERIVE PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRURE DE DEXTROMETORPHANE ET EN PARTICULIER LE BROMHYDRURE DE DEXTROMETROPHANE MONHYDRATE ET QUINIDINE OU UN SEL,....; AUTHORISATION NUMBER AND DATE: EU/1/13/833 20130626 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.